Skip to content
Homepage
Author:
Terns Pharmaceuticals, Inc.
Posted Date:
May 3, 2026
Terns Pharmaceuticals Announces FDA Breakthrough Therapy Designation Granted to TERN-701 for Certain Patients with Chronic Myeloid Leukemia
Terns Pharmaceuticals, Inc.
May 3, 2026
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
Terns Pharmaceuticals, Inc.
April 30, 2026
Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
Terns Pharmaceuticals, Inc.
March 25, 2026
Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences
Terns Pharmaceuticals, Inc.
February 25, 2026
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
Terns Pharmaceuticals, Inc.
February 7, 2026
